Holen Sie sich die Stockscreener-App
2.43
0.83%
0.02
Handel nachbörslich:
2.48
0.05
+2.06%
Schlusskurs vom Vortag:
$2.41
Offen:
$2.49
24-Stunden-Volumen:
561.60K
Relative Volume:
0.14
Marktkapitalisierung:
$283.24M
Einnahmen:
$6.65M
Nettoeinkommen (Verlust:
$-136.32M
KGV:
-2.1173
EPS:
-1.1477
Netto-Cashflow:
$-112.04M
1W Leistung:
-13.06%
1M Leistung:
+15.71%
6M Leistung:
+85.50%
1J Leistung:
+95.97%
1-Tages-Spanne:
$2.39
$2.52
1-Wochen-Bereich:
$2.39
$2.86
52-Wochen-Spanne:
$0.91
$3.23
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
2.43 | 280.91M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-19 | Fortgesetzt | Jefferies | Buy |
| 2025-10-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Fate Therapeutics Inc (FATE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fate Therapeutics, Inc. Revenue Breakdown – NASDAQ:FATE - TradingView
Fate Therapeutics Inc (FATE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
FATE News | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
BlackRock, Inc. Reduces Stake in Fate Therapeutics Inc - GuruFocus
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits
FDA approves clinical testing of CAR T-cell therapy for AAV, other conditions - ANCA Vasculitis News
Fate Therapeutics Inc (FATE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $3.11 - Moomoo
Fate Therapeutics’ FT-839 gains IND clearance - BioWorld News
H.C. Wainwright reiterates Fate Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Fate Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Can Fate Therapeutics (NASDAQ:FATE) Boost Healthcare Stocks? - Kalkine Media
FT819 shows first clinical activity in systemic sclerosis - CRISPR Medicine News
Fate Therapeutics Inc (FATE) Institutional Confidence - TradingKey
Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 - Moomoo
Sector Update: Healthcare - Moomoo
Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 - marketscreener.com
Fate Therapeutics receives FDA clearance for FT839 IND - grafa.com
Fate Therapeutics gains after IND clearance (FATE:NASDAQ) - Seeking Alpha
Fate Therapeutics Receives FDA Clearance Of Investigational New Drug Application For FT839 Product Candidate - marketscreener.com
Fate Therapeutics Announces FDA Clearance of IND for FT839 Dual-CAR T Cell Therapy in Autoimmune Disease - Quiver Quantitative
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate - GlobeNewswire
Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade) - Seeking Alpha
Fate Therapeutics looks to its pipeline as investors weigh long-term prospects - ad-hoc-news.de
Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54 - simplywall.st
Fate Therapeutics Presents Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis At ISSCR 2026 Annual Meeting - marketscreener.com
Fate Therapeutics to present FT819 data at stem cell meeting - Investing.com
Fate Therapeutics to present FT819 data at stem cell meeting By Investing.com - Investing.com Nigeria
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting - The Manila Times
Fate Therapeutics Announces Preliminary FT819 Data in Systemic Sclerosis for ISSCR 2026 Presentation - Quiver Quantitative
Fate Therapeutics to show early FT819 data in systemic sclerosis - Stock Titan
Fate Therapeutics (FATE) Slides to $2.92 as Support Levels Come Into FocusVolume Gap - dars.gov.et
Fate Therapeutics focuses on cell-based immunotherapy and long-term growth prospects - Ad-hoc-news.de
Fate Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline AdvancesEstimate Accuracy - dars.gov.et
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - The Manila Times
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Fate Therapeutics(FATE) Stock Options Chain | Quotes & News - Moomoo
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Value Benchmark - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000 Value Benchmark - marketscreener.com
Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders - StocksToTrade
Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History - Benzinga
F6T Forecast — Price Target — Prediction for 2027 - TradingView
Fate Therapeutics sets out next steps, biotech stock in focus after cash preservation move - Ad-hoc-news.de
Fate Therapeutics, Inc. Actuals & Estimates (DUS:F6T) - TradingView
Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fate Therapeutics, Inc. Actuals & Estimates (TRADEGATE:F6T) - TradingView
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):